Pharmacokinetics, Safety, and Tolerability of the Novel Oral Direct Renin Inhibitor Aliskiren in Elderly Healthy Subjects
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference36 articles.
1. Hypertension in adults across the age spectrum: current outcomes and control in the community;Lloyd-Jones;JAMA,2005
2. Hypertension treatment and control in five European countries, Canada, and the United States;Wolf-Maier;Hypertension,2004
3. The renin-angiotensin-aldosterone system: a specific target for hypertension management;Weir;Am J Hypertens,1999
4. Renin inhibition: what are the therapeutic opportunities?;Fisher;J Am Soc Nephrol,2005
5. Renin inhibition with aliskiren: where are we now, and where are we going?;Azizi;J Hypertens,2006
Cited by 49 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Age-related pharmacokinetics differences were observed between young and elderly populations of a novel PDE5 inhibitor, youkenafil, and its metabolite M459;European Journal of Pharmaceutical Sciences;2024-05
2. Antihypertensive Efficacy of the Direct Renin Inhibitor Aliskiren as Add-on Therapy in Patients with Poorly Controlled Hypertension;Internal Medicine;2016
3. Aliskiren;Meyler's Side Effects of Drugs;2016
4. Can Aliskiren be Considered as a New Novel Drug for Hypertension?;Cureus;2015-11-04
5. State of the art paper Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension;Archives of Medical Science;2014
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3